Wound Healing News and Research

RSS

Helix BioMedix announces additional funding of $2.9M through convertible promissory notes

Helix BioMedix, Inc., a developer of bioactive peptides, announced additional funding in the amount of $2.9 million through convertible promissory notes. The company also announced the addition of Lawrence Blake Jones to its board of directors.

10 Mar 2010

KCI receives reimbursement approval for use of V.A.C. ATS Therapy System in Japan

Kinetic Concepts, Inc. today announced it has received reimbursement approval from Japan’s Health Insurance Bureau for use of the innovative V.A.C. ATS® Therapy System in the country. The approval signifies an important advancement in the company’s plans for market launch in April and follows Japan’s Ministry of Health, Labor and Welfare’s decision in November 2009 to grant final regulatory approval for the product.

8 Mar 2010

Thymosin beta 4 improves neurological functional outcome

REGENERX BIOPHARMACEUTICALS, INC. announced that a research team from the Henry Ford Hospital in Detroit, MI reported that Thymosin beta 4 (Tβ4), administered to rats one day after embolic stroke, improved neurological functional outcome compared to control animals.

6 Mar 2010

Soluble Systems, SWAI launch TheraSkin to jumpstart healing in chronic and acute wounds

Soluble Systems, LLC and the Skin and Wound Allograft Institute, a wholly owned subsidiary of LifeNet Health, have signed a noteworthy agreement to launch TheraSkin™, a biologically active human skin allograft designed to jumpstart healing in chronic and acute wounds.

6 Mar 2010

Proper diagnosis, treatment and good skin care help control acne and rosacea

Acne and rosacea are two seemingly different skin conditions that have one important thing in common: both are chronic and extremely common skin conditions. However, dermatologists recommend that with proper diagnosis, treatment and a healthy dose of good, old-fashioned skin care, acne and rosacea can be less of a nuisance for patients.

5 Mar 2010

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR).

4 Mar 2010

Exposure to blue-violet light may enhance cell growth in wound sites

Today, during the 39th Annual Meeting of the American Association for Dental Research, convening at the Walter E. Washington Convention Center in Washington, DC, lead researcher C. Millan (U.S. Army Dental Corps, Martinez, Georgia) will present a poster of a study titled "A Novel In Vitro Model for Light-Induced Wound Healing."

4 Mar 2010

Article describing novel biological properties of Thymosin beta 4 peptide fragments published

REGENERX BIOPHARMACEUTICALS, INC. announced today that a university research team has published an article ahead of print in FASEB Journal, a high-impact scientific journal, describing novel biological properties of several Thymosin beta 4 (Tβ4) peptide fragments.

27 Feb 2010

Translational Regenerative Medicine Forum in Winston-Salem

A spray-on skin product and an injectable cell therapy for heart attack patients are among 17 regenerative medicine technologies that will be showcased during the Translational Regenerative Medicine Forum, set for April 6-8 in Winston-Salem.

25 Feb 2010

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin.

25 Feb 2010

TWC, TSC announce the grand opening of new facilities at St. John’s Medical Plaza in Santa Monica

Tower Wound Care Center of Santa Monica and Tower Surgical Center are pleased to announce the grand opening of its new state-of-the-art facilities at St. John’s Medical Plaza in Santa Monica, California.

25 Feb 2010

Virginia Life Science Investments completes recapitalization and management restructuring of Cupron

Virginia Life Science Investments, LLC and other investors have completed a recapitalization and management restructuring of Cupron, Inc., a Delaware corporation established in 2001, with principal offices in Modi’in, Israel. The transaction provides significant new capital to support the continued growth and development of Cupron Inc.; as well as the formation and initial capitalization of an independent new entity, Cupron Medical Inc., a Delaware corporation with principal offices in Richmond, VA.

25 Feb 2010

Synovis Life Technologies reports net revenue of $15.2M for first-quarter fiscal 2010

Synovis Life Technologies, Inc., today reported financial results for the first fiscal quarter ended Jan. 31, 2010.

24 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

BIOGUARD wound dressings with Quick-Med’s NIMBUS antimicrobial technology to be sold by Medline Industries

Quick-Med Technologies, Inc. announced today that its licensee, Derma Sciences, Inc., has entered into an exclusive distribution agreement with Medline Industries whereby Medline will market and sell BIOGUARD™ wound dressings with Quick-Med’s proprietary NIMBUS antimicrobial technology. The agreement covers the acute care segment of the health care market, which includes nearly 6,000 hospitals in the United States plus surgery centers, wound care centers, and other associated health care facilities. Sales under this new agreement are expected to start later this month.

18 Feb 2010

Medline Industries signs exclusive distribution agreement with Derma Sciences for BIOGUARD Barrier Dressings

Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.

18 Feb 2010

Advitech to transfer business operations to subsidiary Botaneco Speciality Ingredients

Advitech Inc. announces today its intention to close its office on boulevard Lebourgneuf in Quebec City. Advitech's business operations will be transferred to its subsidiary in Calgary, Botaneco Speciality Ingredients Inc. ("Botaneco"). Following the merger of Advitech and Botaneco in November 2009, this is a significant step towards integrating and optimizing operations of the combined entity.

18 Feb 2010

Derma Sciences announces pricing of public offering of 972,000 shares of its common stock

Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced the pricing of a public offering of 972,000 shares of DSCI common stock and 324,000 warrants to purchase shares of common stock at a price of $5.50.

17 Feb 2010

Generx clinical development opportunities: bioRASI to assist Cardium

Cardium Therapeutics today announced that it has entered into an agreement with bioRASI, an international contract research organization, to assist Cardium in the evaluation of Generx clinical development opportunities within major newly-industrializing markets in Eastern Europe, Asia and Latin America, for patients with chronic coronary artery disease who are either not optimal candidates for or do not have access to costly angioplasty/stenting or cardiac bypass surgery procedures.

17 Feb 2010

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.

16 Feb 2010

Wound Healing News and Research

Helix BioMedix announces additional funding of $2.9M through convertible promissory notes

KCI receives reimbursement approval for use of V.A.C. ATS Therapy System in Japan

Thymosin beta 4 improves neurological functional outcome

Soluble Systems, SWAI launch TheraSkin to jumpstart healing in chronic and acute wounds

Proper diagnosis, treatment and good skin care help control acne and rosacea

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

Exposure to blue-violet light may enhance cell growth in wound sites

Article describing novel biological properties of Thymosin beta 4 peptide fragments published

Translational Regenerative Medicine Forum in Winston-Salem

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

TWC, TSC announce the grand opening of new facilities at St. John’s Medical Plaza in Santa Monica

Virginia Life Science Investments completes recapitalization and management restructuring of Cupron

Synovis Life Technologies reports net revenue of $15.2M for first-quarter fiscal 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

BIOGUARD wound dressings with Quick-Med’s NIMBUS antimicrobial technology to be sold by Medline Industries

Medline Industries signs exclusive distribution agreement with Derma Sciences for BIOGUARD Barrier Dressings

Advitech to transfer business operations to subsidiary Botaneco Speciality Ingredients

Derma Sciences announces pricing of public offering of 972,000 shares of its common stock

Generx clinical development opportunities: bioRASI to assist Cardium

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News